We sent email to our subscribers on August 29th with our new break-out pick: Advaxis (ADXS).
Congratulations to all who followed our alert – ADXS‘s share price doubled in less than 2 weeks!
ADXS Breaks Resistance and Set To Rally
- near term data is released,
- FDA approves orphan drug designations for Company’s head & neck and cervical cancer drugs,
- a licensing or partnership deal is struck, and
- the Company uplists to the NASDAQ or NYSE MKT.
An affiliate of PennyStockHaven.com expects to receive twenty thousand dollars per month for providing consulting and advisory services to Advaxis. The affiliate may also receive up to two hundred thousand restricted shares in the company in the future. This compensation may affect the objectivity of our profile of the company. You should do your own homework and consult an investment professional before making any investment decisions. Read our full disclaimer here.